Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003951 · ClinicalTrials.gov registry record · Phase 2
DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00003951 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 37 participants.
The verdict
NCT00003951, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have metastatic cancer of the pancreas that has not been previously treated or that has not responded to previous chemotherapy.
Interventions
- DRUG exatecan mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 1999-06 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003951
The ClinicalTrials.gov registry entry for NCT00003951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which exatecan mesylate is the first listed.
NCT00003951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003951 about?
NCT00003951 is a clinical study titled "DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have metastatic cancer of the pancreas that has not been previously treated or that has not...
What is the current status of trial NCT00003951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 1999-06. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00003951?
The interventions under investigation include: exatecan mesylate (DRUG).
Who is sponsoring clinical trial NCT00003951?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.